News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Videos|July 22, 2022

Safety, efficacy of berdazimer gel for molluscum contagiosum

Author(s)Kaitlyn Bader

Stephen Stripling, MD, FAAP, discusses results published in JAMA Dermatology about the efficacy and safety of berdazimer gel 10.3% for the treatment of molluscum contagiosum.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Druhan Howell, MD, discusses ACAAI tapinarof data for pediatric atopic dermatitis

Druhan Howell, MD, discusses ACAAI tapinarof data for pediatric atopic dermatitis

ByDruhan Howell, MD

November 25th 2025

FDA accepts roflumilast cream 0.3% sNDA to treat plaque psoriasis in children 2 to 5 years | Image credit: Contemporary Pediatrics

FDA accepts roflumilast cream 0.3% sNDA to treat plaque psoriasis in children 2 to 5 years

ByJoshua Fitch, Senior Editor

November 17th 2025

Tapinarof cream, 1% (VTAMA) shows early improvements in pediatric atopic dermatitis | Image Credit: © Ruslan Ivantsov - stock.adobe.com.

Tapinarof cream, 1% (VTAMA) shows early improvements in pediatric atopic dermatitis

ByMorgan Ebert, Managing Editor

November 14th 2025

A teenage girl with acne lesions on her forehead

A teenage girl with acne lesions on her forehead

ByAditi Rao,Bernard Cohen, MD

October 30th 2025

Upadacitinib achieves 50% reduction in Total Vitiligo Area Scoring Index at 48 weeks | Image Credit: © Liga Cerina - © Liga Cerina - stock.adobe.com.

Upadacitinib achieves 50% reduction in Total Vitiligo Area Scoring Index at 48 weeks

ByJoshua Fitch, Senior Editor

October 29th 2025

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

In-Person + Virtual Event

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

January 23, 2026

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FDA approves gepotidacin as oral treatment for urogenital gonorrhea

FDA approves powder formulation of trofinetide for Rett syndrome

FDA approves berotralstat for patients aged 2 to 11 years with hereditary angioedema

FDA approves Nuzolvence (zoliflodacin) for treatment of uncomplicated urogenital gonorrhea in 12 years and up

Edward Hook, MD, reacts to the FDA approval of zoliflodacin for uncomplicated urogenital gonorrhea

© 2025 MJH Life Sciences^®

All rights reserved.